-
1
-
-
0037205048
-
The phosphoinositide 3-kinase pathway
-
DOI 10.1126/science.296.5573.1655
-
Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-7. (Pubitemid 34579158)
-
(2002)
Science
, vol.296
, Issue.5573
, pp. 1655-1657
-
-
Cantley, L.C.1
-
2
-
-
0028601306
-
Molecular cloning, cDNA sequence and chromosomal localization of the human phosphatidylinositol-3-kinase p110 alpha (PIK3CA) gene
-
Volinia S, Hiles I, Ormondroyd E, Nizetic D, Antonacci R, Rocchi M, et al. Molecular cloning, cDNA sequence and chromosomal localization of the human phosphatidylinositol-3-kinase p110 alpha (PIK3CA) gene. Genomics 1994; 24:472-7.
-
(1994)
Genomics
, vol.24
, pp. 472-477
-
-
Volinia, S.1
Hiles, I.2
Ormondroyd, E.3
Nizetic, D.4
Antonacci, R.5
Rocchi, M.6
-
3
-
-
33344462540
-
Mutation of the PIK3CA oncogene in human cancers
-
DOI 10.1038/sj.bjc.6602970
-
Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006; 94:455-9. (Pubitemid 43289745)
-
(2006)
British Journal of Cancer
, vol.94
, Issue.4
, pp. 455-459
-
-
Karakas, B.1
Bachman, K.E.2
Park, B.H.3
-
4
-
-
11144358645
-
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
-
DOI 10.1126/science.1096502
-
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304:554. (Pubitemid 38541907)
-
(2004)
Science
, vol.304
, Issue.5670
, pp. 554
-
-
Samuels, Y.1
Wang, Z.2
Bardelli, A.3
Silliman, N.4
Ptak, J.5
Szabo, S.6
Yan, H.7
Gazdar, A.8
Powell, S.M.9
Riggins, G.J.10
Willson, J.K.V.11
Markowitz, S.12
Kinzler, K.W.13
Vogelstein, B.14
Velculescu, V.E.15
-
5
-
-
16644393213
-
The PIK3CA gene is mutated with high frequency in human breast cancers
-
Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; 3:772-5. (Pubitemid 41351083)
-
(2004)
Cancer Biology and Therapy
, vol.3
, Issue.8
, pp. 772-775
-
-
Bachman, K.E.1
Argani, P.2
Samuels, Y.3
Silliman, N.4
Ptak, J.5
Szabo, S.6
Konishi, H.7
Karakas, B.8
Blair, B.G.9
Lin, C.10
Peters, B.A.11
Velculescu, V.E.12
Park, B.H.13
-
6
-
-
7444250290
-
Mutation of the PIK3CA gene in ovarian and breast cancer
-
DOI 10.1158/0008-5472.CAN-04-2933
-
Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64:7678-81. (Pubitemid 39446895)
-
(2004)
Cancer Research
, vol.64
, Issue.21
, pp. 7678-7681
-
-
Campbell, I.G.1
Russell, S.E.2
Choong, D.Y.H.3
Montgomery, K.G.4
Ciavarella, M.L.5
Hooi, C.S.F.6
Cristiano, B.E.7
Pearson, R.B.8
Phillips, W.A.9
-
7
-
-
20144387695
-
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
-
DOI 10.1158/0008-5472-CAN-04-3913
-
Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis and ERBB2 and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65:2554-9. (Pubitemid 40490050)
-
(2005)
Cancer Research
, vol.65
, Issue.7
, pp. 2554-2559
-
-
Saal, L.H.1
Holm, K.2
Maurer, M.3
Memeo, L.4
Su, T.5
Wang, X.6
Yu, J.S.7
Malmstrom, P.-O.8
Mansukhani, M.9
Enoksson, J.10
Hibshoosh, H.11
Borg, A.12
Parsons, R.13
-
8
-
-
0034920457
-
Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer
-
DOI 10.1038/modpathol.3880371
-
Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001; 14:672-6. (Pubitemid 32667211)
-
(2001)
Modern Pathology
, vol.14
, Issue.7
, pp. 672-676
-
-
Depowski, P.L.1
Rosenthal, S.I.2
Ross, J.S.3
-
9
-
-
0032857217
-
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast
-
Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999; 155:1253-60. (Pubitemid 29488932)
-
(1999)
American Journal of Pathology
, vol.155
, Issue.4
, pp. 1253-1260
-
-
Perren, A.1
Weng, L.-P.2
Boag, A.H.3
Ziebold, U.4
Thakore, K.5
Dahia, P.L.M.6
Komminoth, P.7
Lees, J.A.8
Mulligan, L.M.9
Mutter, G.L.10
Eng, C.11
-
10
-
-
34250687198
-
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
-
DOI 10.1073/pnas.0702507104
-
Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104:7564-9. (Pubitemid 47185946)
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, Issue.18
, pp. 7564-7569
-
-
Saal, L.H.1
Johansson, P.2
Holm, K.3
Gruvberger-Saal, S.K.4
She, Q.-B.5
Maurer, M.6
Koujak, S.7
Ferrando, A.A.8
Malmstrom, P.9
Memeo, L.10
Isola, J.11
Bendahl, P.-O.12
Rosen, N.13
Hibshoosh, H.14
Ringner, M.15
Borg, A.16
Parsons, R.17
-
11
-
-
34547172596
-
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
-
DOI 10.1038/nature05933, PII NATURE05933
-
Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448:439-44. (Pubitemid 47123510)
-
(2007)
Nature
, vol.448
, Issue.7152
, pp. 439-444
-
-
Carpten, J.D.1
Faber, A.L.2
Horn, C.3
Donoho, G.P.4
Briggs, S.L.5
Robbins, C.M.6
Hostetter, G.7
Boguslawski, S.8
Moses, T.Y.9
Savage, S.10
Uhlik, M.11
Lin, A.12
Du, J.13
Qian, Y.-W.14
Zeckner, D.J.15
Tucker-Kellogg, G.16
Touchman, J.17
Patel, K.18
Mousses, S.19
Bittner, M.20
Schevitz, R.21
Lai, M.-H.T.22
Blanchard, K.L.23
Thomas, J.E.24
more..
-
12
-
-
52149086562
-
AKT1(E17K) in human solid tumours
-
Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, et al. AKT1(E17K) in human solid tumours. Oncogene 2008; 27:5648-50.
-
(2008)
Oncogene
, vol.27
, pp. 5648-5650
-
-
Bleeker, F.E.1
Felicioni, L.2
Buttitta, F.3
Lamba, S.4
Cardone, L.5
Rodolfo, M.6
-
13
-
-
51049118140
-
An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer
-
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer. Cancer Res 2008; 68:6084-91.
-
(2008)
Cancer Res
, vol.68
, pp. 6084-6091
-
-
Stemke-Hale, K.1
Gonzalez-Angulo, A.M.2
Lluch, A.3
Neve, R.M.4
Kuo, W.L.5
Davies, M.6
-
14
-
-
43249115083
-
Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
-
DOI 10.1038/sj.bjc.6604212, PII 6604212
-
Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 2008; 98:1533-5. (Pubitemid 351652321)
-
(2008)
British Journal of Cancer
, vol.98
, Issue.9
, pp. 1533-1535
-
-
Kim, M.S.1
Jeong, E.G.2
Yoo, N.J.3
Lee, S.H.4
-
15
-
-
77951586944
-
Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations
-
Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, et al. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene 2010; 29:2337-45.
-
(2010)
Oncogene
, vol.29
, pp. 2337-2345
-
-
Lauring, J.1
Cosgrove, D.P.2
Fontana, S.3
Gustin, J.P.4
Konishi, H.5
Abukhdeir, A.M.6
-
16
-
-
34249026448
-
Binding of Ras to Phosphoinositide 3-Kinase p110alpha Is Required for Ras- Driven Tumorigenesis in Mice
-
DOI 10.1016/j.cell.2007.03.051, PII S009286740700520X
-
Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2007; 129:957-68. (Pubitemid 46802703)
-
(2007)
Cell
, vol.129
, Issue.5
, pp. 957-968
-
-
Gupta, S.1
Ramjaun, A.R.2
Haiko, P.3
Wang, Y.4
Warne, P.H.5
Nicke, B.6
Nye, E.7
Stamp, G.8
Alitalo, K.9
Downward, J.10
-
17
-
-
14544271905
-
Positive and negative regulation of insulin signaling through IRS-1 phosphorylation
-
DOI 10.1016/j.biochi.2004.10.019
-
Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 2005; 87:99-109. (Pubitemid 40298772)
-
(2005)
Biochimie
, vol.87
, Issue.1 SPEC. ISS
, pp. 99-109
-
-
Gual, P.1
Le, M.-B.Y.2
Tanti, J.-F.3
-
18
-
-
0028214293
-
Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer
-
Sharma AK, Horgan K, Douglas-Jones A, McClelland R, Gee J, Nicholson R. Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br J Cancer 1994; 69:1032-7. (Pubitemid 24161855)
-
(1994)
British Journal of Cancer
, vol.69
, Issue.6
, pp. 1032-1037
-
-
Sharma, A.K.1
Horgan, K.2
Douglas-Jones, A.3
McClelland, R.4
Gee, J.5
Nicholson, R.6
-
19
-
-
0028212870
-
The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study
-
Klijn JG, Look MP, Portengen H, Alexieva-Figusch J, van Putten WL, Foekens JA. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 1994; 29:73-83. (Pubitemid 24104839)
-
(1994)
Breast Cancer Research and Treatment
, vol.29
, Issue.1
, pp. 73-83
-
-
Klijn, J.G.M.1
Look, M.P.2
Portengen, H.3
Alexieva-Figusch, J.4
Van, P.W.L.J.5
Fockens, J.A.6
-
20
-
-
0024822342
-
Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu
-
Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 1989; 34:123-31. (Pubitemid 20061773)
-
(1989)
Journal of Steroid Biochemistry
, vol.34
, Issue.1-6
, pp. 123-131
-
-
Harris, A.L.1
Nicholson, S.2
Sainsbury, J.R.C.3
Farndon, J.4
Wright, C.5
-
21
-
-
70249092544
-
Immunohistochemical expression and significance of epidermal growth factor receptor (EGFR) in breast cancer
-
Meche A, Cimpean AM, Raica M. Immunohistochemical expression and significance of epidermal growth factor receptor (EGFR) in breast cancer. Rom J Morphol Embryol 2009; 50:217-21.
-
(2009)
Rom J Morphol Embryol
, vol.50
, pp. 217-221
-
-
Meche, A.1
Cimpean, A.M.2
Raica, M.3
-
22
-
-
23944464495
-
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
-
DOI 10.1200/JCO.2005.08.326
-
Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005; 23:5323-33. (Pubitemid 46206986)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.23
, pp. 5323-5333
-
-
Baselga, J.1
Albanell, J.2
Ruiz, A.3
Lluch, A.4
Gascon, P.5
Guillem, V.6
Gonzalez, S.7
Sauleda, S.8
Marimon, I.9
Tabernero, J.M.10
Koehler, M.T.11
Rojo, F.12
-
23
-
-
65549098841
-
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
-
Corkery B, Crown J, Clynes M, O'Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009; 20:862-7.
-
(2009)
Ann Oncol
, vol.20
, pp. 862-867
-
-
Corkery, B.1
Crown, J.2
Clynes, M.3
O'Donovan, N.4
-
24
-
-
58549095879
-
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
-
Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, et al. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci USA 2008; 105:20864-9.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 20864-20869
-
-
Di Nicolantonio, F.1
Arena, S.2
Gallicchio, M.3
Zecchin, D.4
Martini, M.5
Flonta, S.E.6
-
25
-
-
62449130185
-
Knockin of mutant PIK3CA activates multiple oncogenic pathways
-
Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci USA 2009; 106:2835-40.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 2835-2840
-
-
Gustin, J.P.1
Karakas, B.2
Weiss, M.B.3
Abukhdeir, A.M.4
Lauring, J.5
Garay, J.P.6
-
26
-
-
70350539589
-
Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells
-
Vitolo MI, Weiss MB, Szmacinski M, Tahir K, Waldman T, Park BH, et al. Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells. Cancer Res 2009; 69:8275-83.
-
(2009)
Cancer Res
, vol.69
, pp. 8275-8283
-
-
Vitolo, M.I.1
Weiss, M.B.2
Szmacinski, M.3
Tahir, K.4
Waldman, T.5
Park, B.H.6
-
27
-
-
77951586944
-
Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations
-
Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, et al. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene 2010; 29:2337-45.
-
(2010)
Oncogene
, vol.29
, pp. 2337-2345
-
-
Lauring, J.1
Cosgrove, D.P.2
Fontana, S.3
Gustin, J.P.4
Konishi, H.5
Abukhdeir, A.M.6
-
28
-
-
0036969268
-
Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer
-
Yoon DS, Wersto RP, Zhou W, Chrest FJ, Garrett ES, Kwon TK, et al. Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. Am J Pathol 2002; 161:391-7. (Pubitemid 36142147)
-
(2002)
American Journal of Pathology
, vol.161
, Issue.2
, pp. 391-397
-
-
Yoon, D.-S.1
Wersto, R.P.2
Zhou, W.3
Chrest, F.J.4
Garrett, E.S.5
Kyu, K.T.6
Gabrielson, E.7
-
29
-
-
0025129726
-
Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10
-
Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990; 50:6075-86. (Pubitemid 20331424)
-
(1990)
Cancer Research
, vol.50
, Issue.18
, pp. 6075-6086
-
-
Soule, H.D.1
Maloney, T.M.2
Wolman, S.R.3
Peterson Jr., W.D.4
Brenz, R.5
McGrath, C.M.6
Russo, J.7
Pauley, R.J.8
Jones, R.F.9
Brooks, S.C.10
-
30
-
-
34250749822
-
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer
-
DOI 10.1158/1078-0432.CCR-06-1609
-
Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007; 13:3577-84. (Pubitemid 46955118)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.12
, pp. 3577-3584
-
-
Perez-Tenorio, G.1
Alkhori, L.2
Olsson, B.3
Waltersson, M.A.4
Nordenskjold, B.5
Rutqvist, L.E.6
Skoog, L.7
Stal, O.8
-
31
-
-
0036216405
-
STI571 (Gleevec) as a paradigm for cancer therapy
-
Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2002; 8:14-8.
-
(2002)
Trends Mol Med
, vol.8
, pp. 14-18
-
-
Druker, B.J.1
-
32
-
-
55249120170
-
Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy
-
Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008; 455:1205-9.
-
(2008)
Nature
, vol.455
, pp. 1205-1209
-
-
Wang, Z.1
Smith, K.S.2
Murphy, M.3
Piloto, O.4
Somervaille, T.C.5
Cleary, M.L.6
-
33
-
-
77949268513
-
GSK3beta regulates differentiation and growth arrest in glioblastoma
-
Korur S, Huber RM, Sivasankaran B, Petrich M, Morin P Jr, Hemmings BA, et al. GSK3beta regulates differentiation and growth arrest in glioblastoma. PLoS One 2009; 4:7443.
-
(2009)
PLoS One
, vol.4
, pp. 7443
-
-
Korur, S.1
Huber, R.M.2
Sivasankaran, B.3
Petrich, M.4
Morin Jr., P.5
Hemmings, B.A.6
-
34
-
-
57049124808
-
Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells
-
Beurel E, Blivet-Van Eggelpoel MJ, Kornprobst M, Moritz S, Delelo R, Paye F, et al. Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells. Biochem Pharmacol 2009; 77:54-65.
-
(2009)
Biochem Pharmacol
, vol.77
, pp. 54-65
-
-
Beurel, E.1
Blivet-Van Eggelpoel, M.J.2
Kornprobst, M.3
Moritz, S.4
Delelo, R.5
Paye, F.6
-
35
-
-
34147168760
-
Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells
-
DOI 10.1158/1535-7163.MCT-06-0665
-
Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther 2007; 6:1151-8. (Pubitemid 46554586)
-
(2007)
Molecular Cancer Therapeutics
, vol.6
, Issue.3
, pp. 1151-1158
-
-
Kunnimalaiyaan, M.1
Vaccaro, A.M.2
Ndiaye, M.A.3
Chen, H.4
-
36
-
-
33746239119
-
Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells
-
DOI 10.1038/sj.cr.7310078, PII 7310078
-
Cao Q, Lu X, Feng YJ. Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res 2006; 16:671-7. (Pubitemid 44091443)
-
(2006)
Cell Research
, vol.16
, Issue.7
, pp. 671-677
-
-
Cao, Q.1
Lu, X.2
Feng, Y.-J.3
-
37
-
-
59649113343
-
Lithium poisoning: Is determination of the red blood cell lithium concentration useful?
-
(Phila)
-
El Balkhi S, Megarbane B, Poupon J, Baud FJ, Galliot-Guilley M. Lithium poisoning: is determination of the red blood cell lithium concentration useful? Clin Toxicol (Phila) 2009; 47:8-13.
-
(2009)
Clin Toxicol
, vol.47
, pp. 8-13
-
-
El Balkhi, S.1
Megarbane, B.2
Poupon, J.3
Baud, F.J.4
Galliot-Guilley, M.5
-
38
-
-
2342471392
-
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib
-
DOI 10.1056/NEJMoa040938
-
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39. (Pubitemid 38637993)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.21
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
Louis, D.N.11
Christiani, D.C.12
Settleman, J.13
Haber, D.A.14
-
39
-
-
2342624080
-
EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy
-
DOI 10.1126/science.1099314
-
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500. (Pubitemid 38720929)
-
(2004)
Science
, vol.304
, Issue.5676
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
Herman, P.7
Kaye, F.J.8
Lindeman, N.9
Boggon, T.J.10
Naoki, K.11
Sasaki, H.12
Fujii, Y.13
Eck, M.J.14
Sellers, W.R.15
Johnson, B.E.16
Meyerson, M.17
-
40
-
-
4444344330
-
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
-
DOI 10.1073/pnas.0405220101
-
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-11. (Pubitemid 39209661)
-
(2004)
Proceedings of the National Academy of Sciences of the United States of America
, vol.101
, Issue.36
, pp. 13306-13311
-
-
Pao, W.1
Miller, V.2
Zakowski, M.3
Doherty, J.4
Politi, K.5
Sarkaria, I.6
Singh, B.7
Heelan, R.8
Rusch, V.9
Fulton, L.10
Mardis, E.11
Kupfer, D.12
Wilson, R.13
Kris, M.14
Varmus, H.15
-
41
-
-
69949186250
-
Screening for epidermal growth factor receptor mutations in lung cancer
-
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361:958-67.
-
(2009)
N Engl J Med
, vol.361
, pp. 958-967
-
-
Rosell, R.1
Moran, T.2
Queralt, C.3
Porta, R.4
Cardenal, F.5
Camps, C.6
-
42
-
-
67650471685
-
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
-
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-34.
-
(2009)
N Engl J Med
, vol.361
, pp. 123-134
-
-
Fong, P.C.1
Boss, D.S.2
Yap, T.A.3
Tutt, A.4
Wu, P.5
Mergui-Roelvink, M.6
-
43
-
-
17244373777
-
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
-
DOI 10.1038/nature03445
-
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21. (Pubitemid 40559006)
-
(2005)
Nature
, vol.434
, Issue.7035
, pp. 917-921
-
-
Farmer, H.1
McCabe, H.2
Lord, C.J.3
Tutt, A.H.J.4
Johnson, D.A.5
Richardson, T.B.6
Santarosa, M.7
Dillon, K.J.8
Hickson, I.9
Knights, C.10
Martin, N.M.B.11
Jackson, S.P.12
Smith, G.C.M.13
Ashworth, A.14
-
44
-
-
17244375049
-
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
-
DOI 10.1038/nature03443
-
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-7. (Pubitemid 40559005)
-
(2005)
Nature
, vol.434
, Issue.7035
, pp. 913-917
-
-
Bryant, H.E.1
Schultz, N.2
Thomas, H.D.3
Parker, K.M.4
Flower, D.5
Lopez, E.6
Kyle, S.7
Meuth, M.8
Curtin, N.J.9
Helleday, T.10
-
45
-
-
69949170092
-
Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a
-
Fine B, Hodakoski C, Koujak S, Su T, Saal LH, Maurer M, et al. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science 2009; 325:1261-5.
-
(2009)
Science
, vol.325
, pp. 1261-1265
-
-
Fine, B.1
Hodakoski, C.2
Koujak, S.3
Su, T.4
Saal, L.H.5
Maurer, M.6
-
46
-
-
0029587224
-
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
-
DOI 10.1038/378785a0
-
Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-9. (Pubitemid 26004411)
-
(1995)
Nature
, vol.378
, Issue.6559
, pp. 785-789
-
-
Cross, D.A.E.1
Alessi, D.R.2
Cohen, P.3
Andjelkovich, M.4
Hemmings, B.A.5
-
47
-
-
22544433759
-
Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin
-
DOI 10.1016/j.molcel.2005.06.009, PII S1097276505013870
-
Ding Q, Xia W, Liu JC, Yang JY, Lee DF, Xia J, et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 2005; 19:159-70. (Pubitemid 41019664)
-
(2005)
Molecular Cell
, vol.19
, Issue.2
, pp. 159-170
-
-
Ding, Q.1
Xia, W.2
Liu, J.-C.3
Yang, J.-Y.4
Lee, D.-F.5
Xia, J.6
Bartholomeusz, G.7
Li, Y.8
Pan, Y.9
Li, Z.10
Bargou, R.C.11
Qin, J.12
Lai, C.-C.13
Tsai, F.-J.14
Tsai, C.-H.15
Hung, M.-C.16
-
48
-
-
4444278403
-
HER-2 amplification, HER-1 expression and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study
-
Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, et al. HER-2 amplification, HER-1 expression and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004; 10:5670-6.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 5670-5676
-
-
Arpino, G.1
Green, S.J.2
Allred, D.C.3
Lew, D.4
Martino, S.5
Osborne, C.K.6
-
49
-
-
0035971181
-
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for antiestrogen resistance
-
Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for antiestrogen resistance. J Biol Chem 2001; 276:9817-24.
-
(2001)
J Biol Chem
, vol.276
, pp. 9817-9824
-
-
Campbell, R.A.1
Bhat-Nakshatri, P.2
Patel, N.M.3
Constantinidou, D.4
Ali, S.5
Nakshatri, H.6
-
50
-
-
5144226211
-
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
-
DOI 10.1016/j.ccr.2004.06.022, PII S1535610804002107
-
Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6:117-27. (Pubitemid 39485684)
-
(2004)
Cancer Cell
, vol.6
, Issue.2
, pp. 117-127
-
-
Nagata, Y.1
Lan, K.-H.2
Zhou, X.3
Tan, M.4
Esteva, F.J.5
Sahin, A.A.6
Klos, K.S.7
Li, P.8
Monia, B.P.9
Nguyen, N.T.10
Hortobagyi, G.N.11
Hung, M.-C.12
Yu, D.13
-
51
-
-
35148885729
-
A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer
-
DOI 10.1016/j.ccr.2007.08.030, PII S1535610807002620
-
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12:395-402. (Pubitemid 47539306)
-
(2007)
Cancer Cell
, vol.12
, Issue.4
, pp. 395-402
-
-
Berns, K.1
Horlings, H.M.2
Hennessy, B.T.3
Madiredjo, M.4
Hijmans, E.M.5
Beelen, K.6
Linn, S.C.7
Gonzalez-Angulo, A.M.8
Stemke-Hale, K.9
Hauptmann, M.10
Beijersbergen, R.L.11
Mills, G.B.12
De Van, V.M.J.13
Bernards, R.14
-
52
-
-
34548710863
-
Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras-mediated transformation
-
DOI 10.1158/0008-5472.CAN-07-0108
-
Konishi H, Karakas B, Abukhdeir AM, Lauring J, Gustin JP, Garay JP, et al. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res 2007; 67:8460-7. (Pubitemid 47437419)
-
(2007)
Cancer Research
, vol.67
, Issue.18
, pp. 8460-8467
-
-
Konishi, H.1
Karakas, B.2
Abukhdeir, A.M.3
Lauring, J.4
Gustin, J.P.5
Garay, J.P.6
Konishi, Y.7
Gallmeier, E.8
Bachman, K.E.9
Ben, H.P.10
|